Business Wire

Genesis Q1 2022 Report Reflects Another Strong Quarter Amid Market Uncertainty

29.4.2022 16:15:00 EEST | Business Wire | Press release

Share

Genesis, a digital asset industry pioneer and digital currency prime brokerage, today released its Q1 2022 Market Observations Report, highlighting major trends across institutional digital asset markets. The report provides a breakdown of Genesis’ lending, derivatives, spot, and custody activities across Q1 2022, along with in-depth insight from the Genesis lending and derivatives desks on trends such as the growing adoption of permissioned DeFi protocols, the gradual institutionalization in debt markets and the continued growing interest from the traditional financial community in stablecoin derivatives.

The first quarter was characterized by Genesis’ notable growth across most of its operations – including another record quarter in derivatives trading activity – even against the backdrop of lower overall crypto market volumes and high levels of uncertainty throughout most asset types. Highlights during the quarter include the following:

  • In Q1 2022, the USD amount of active loans outstanding grew to $14.6 billion against declining prices, a level 17% higher than at the end of the previous quarter, and 62% higher than at the end of Q1 2021.
  • As of March 31, cumulative loan originations had reached $195 billion.
  • The notional volume traded by the derivatives desk in Q1 reached $27.8 billion, up 33% from Q4, inclusive of negotiated block- and exchange- traded futures.
  • Assets under custody increased by 23% over Q1.
  • The USD volume of assets moved from Genesis Custody to the Genesis trading or lending desks increased by 141% vs Q4 2022.
  • Genesis’ headcount increased 22% over the quarter to reach 208 employees across three continents.

“Institutions continue to develop their crypto strategies and strengthen their understanding of this industry, even amid the market uncertainty that has marked the start to this year,” said Michael Moro, CEO of Genesis. “As we continue to deepen engagement with our clients across Genesis’ wide range of products, we are committed to further expanding our market share and delivering innovative strategies for clients to access this growing asset class.”

Derivatives and Spot Trading

Genesis saw another record quarter in derivatives trading activity, with over $27.8 billion in notional value traded globally. This figure includes bilateral OTC, negotiated block futures trades and exchange-traded volumes, representing 33% quarter-on-quarter growth. In Q1, Genesis was also #1 in market share for blocked BTC and ETH Deribit-cleared derivatives via Paradigm with over $6.6 billion transacted1. The firm also printed the first ever ETH and BTC Micro options trades on the CME in March. Additionally, the Genesis derivatives desk traded 61 different assets in the first quarter, with $4.7 billion notional traded in altcoin derivatives – Genesis’ highest quarterly total yet as it continues to prove its ability to help clients hedge and take directional positions in even the most esoteric of markets.

The Genesis spot desk traded over $11.4 billion in volume in Q1, with the continuing trend toward greater diversification of assets. BTC comprised 48% of the traded volume, in line with last quarter, while ETH saw a drop from 33% to 23% of total traded volume in Q1. The Genesis spot desk also saw a notable increase in activity across assets such as LUNA, SOL, AVAX, ZEC, LINK, ATOM and GALA.

Crypto Lending

Despite a market environment faced with many uncertainties, as valuations across all crypto assets nearly halved from November peaks, the Genesis lending desk originated over $44.3 billion in loans in Q1 2022, bringing cumulative originations since inception in March 2018 to $195 billion. Active loans outstanding also climbed to $14.6 billion to close the quarter, up 17% from the end of 2021.

The strong level of activity Genesis saw in Q1 – despite the weak market environment – was mainly due to organic volume driven by new institutions entering the industry and by increasing demand for cash loans, which allowed Genesis to capitalize on its core competitive strengths as a leading digital asset prime broker.

Custody

Assets under custody increased by 23% quarter-on-quarter, while the USD volume of assets moved from Genesis Custody to the Genesis trading or lending desks increased by 141% over the same period. This comes as Genesis continues to integrate its lending and trading desks more tightly into its SOC 2 Type 1-audited and FCA-registered custodian.

The number of customers onboarded to Genesis Custody also increased by 36% over the quarter, driven mainly by large public and private mining companies, venture capital firms and other traditional asset managers on a global level, following Genesis’ FCA registration and the roll out of its 24/5 support.

The Genesis Q1 2022 Market Observations Report provides a comprehensive look into key market activity through insights from the firm’s spot trading, derivatives trading, lending, custody, treasury and prime brokerage businesses. To read the full Q1 2022 Market Observations Report, click here.

About Genesis

Genesis is a full-service digital currency prime brokerage providing a single point of access for select qualified individuals and global institutional investors. Genesis combines unrivaled operational excellence, a seamless user experience, and best-in-class client service to provide the full suite of services global investors require to manage their digital asset portfolios.

The firm offers sophisticated market participants a fully integrated platform to trade, borrow, lend, and custody digital assets, creating new opportunities for yield while increasing capital efficiency for counterparties.

Genesis is a wholly owned subsidiary of Digital Currency Group (DCG), one of the largest private investors in blockchain and digital asset companies.

For more information on Genesis, please visit genesistrading.com and follow @GenesisTrading on Twitter.

____________________________
1 Per Paradigm statistics as of April 28, 2022

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Marc Yaklofsky
press@genesistrading.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Techtronic Industries Delivers Strong First Half Performance4.8.2026 14:20:00 EEST | Press release

Techtronic Industries Co. Ltd. (“TTI” or the “Group”) (stock code: HK: 0669, ADR symbol: TTNDY), a global cordless power tool, outdoor power equipment and floorcare & cleaning company, is pleased to announce its results for the six-month period ended June 30, 2026. The Group delivered record first half results in 2026, with revenue growing 5.9% to US$8.3 billion. Its two leading brands, MILWAUKEE and RYOBI, both delivered a strong performance in the first half of 2026, growing at a combined 8.2% underlying growth rate in local currency. TTI delivered record first half results in 2026, with revenue growing 5.9% to US$8.3 billion and net profit increasing 17.5% to US$738 million. Our global MILWAUKEE business grew 10.5% on an underlying basis in local currency, after adjusting for the planned 2025 timing impact related to the MILWAUKEE Americas ERP system conversion. RYOBI, the #1 global consumer cordless tool and outdoor products brand, grew 1.7% in local currency to US$1.9 billion in t

WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 12:00:00 EEST | Press release

WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, uses biomarker data, including temperature and heart rate data, to identify fertile and non-fertile days, helping users prevent pregnancy without hormones while also providing fertility insights. Beyond birth control, the app

Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 11:00:00 EEST | Press release

Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphatax's long-term vision for the future of tax technology. By bringing these transfer pric

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release

Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye